5 Things Biogen Idec Inc's Management Wants You to Know
Pipeline data, new drug launches, and sales of established drugs top the list.
Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary an
Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
$20 Billion Market: What’s the Best Stock to Buy?
Three drug companies to watch as biologics come off patent and investors anticipate a biosimilar boom -- here's what you need to know.
Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Momenta shares rose by more than 10% earlier today on optimism it will overcome headwinds.
Waiting for the Momenta to Regain
Momenta Pharmaceuticals waits on potential partner(s), the FDA, and the court system.